Taking a High Dose of Wegovy: How Dose Escalation Works and What to Expect

What 'high dose' actually means on the Wegovy schedule

Dose escalation on Wegovy isn't a ladder you climb as fast as possible. The starting point (0.25 mg) exists to settle your system gradually, not because it's expected to produce meaningful weight loss on its own. The therapeutic work begins to build from 1.0 mg upward, and most clinical trial evidence is anchored to the 2.4 mg maintenance dose. The full Wegovy dose schedule spans five steps before you reach that 2.4 mg level.

The arrival of a dedicated 7.2 mg weekly pen, approved by the MHRA on 14 April 2026, shifts the ceiling. This single-dose pen is licensed for adults with a BMI of 30 or above, and trials reported average weight loss of around 20.7% over 72 weeks at this dose, approaching results seen with the highest doses of tirzepatide. For context, the STEP 1 trial (published in the New England Journal of Medicine) reported around 15% average body-weight reduction at 2.4 mg over 68 weeks. The 7.2 mg data narrows that gap considerably.

None of this means 7.2 mg is right for everyone. A prescriber looks at how well each prior dose was tolerated, whether weight loss has plateaued, and whether there are any clinical reasons to stay where you are. If you want a clearer picture of how high the Wegovy dosage can go, that question is worth exploring in depth.

The factors your prescriber is weighing before moving you up

Dose increases aren't automatic. Four weeks is the typical minimum at each level before escalating, but your prescriber may hold you at an intermediate dose for longer (sometimes much longer) if nausea, vomiting, or other gastrointestinal symptoms are still noticeable. The goal is to reach the highest dose you can tolerate well, not the highest dose on paper.

There's an important concept buried in the guidance here. NICE's recommendation for semaglutide (TA875) includes a review point at six months on the maintenance dose: if weight loss is below 5% at that stage, continuing is reconsidered. That's not a failure, it's clinical care working as intended, matching the medicine to the person rather than the other way around. You can read the NICE semaglutide appraisal directly if you want the committee's full reasoning.

Side effects tend to be most pronounced after a dose increase and usually settle within a couple of weeks. If you're wondering whether your current dose has gone too high given how you're feeling, this page on recognising a dose that's too high sets out what to watch for. A quick habit worth building: before each new pen, check whether you've had any persistent symptoms in the last week that you haven't mentioned to your prescriber. It takes under a minute and catches the things people mean to report but forget.

Side effects that tend to intensify at higher doses

The side-effect profile of Wegovy is largely gastrointestinal, and it follows a predictable pattern: symptoms are typically most noticeable when a dose is first introduced and then ease as the body adjusts. At higher doses (particularly 1.7 mg and above) that initial adjustment can be more pronounced for some people. Common effects include nausea, loose stools, constipation, acid reflux, and fatigue. Most are mild to moderate and transient.

There are some signals that need medical attention rather than patience. Severe, persistent stomach pain that extends toward the back, with or without vomiting, should not be waited out, this can indicate acute pancreatitis, which the MHRA's Drug Safety Update programme has flagged as an infrequent but serious risk with GLP-1 medicines. Gallbladder symptoms and signs of significant dehydration from severe vomiting or diarrhoea also warrant prompt contact with a healthcare professional. For a thorough breakdown, side effects at higher Wegovy doses covers this in full, and what to do if you think you've taken too high a dose addresses the accidental overshoot scenario.

Reporting any unexpected reaction through the MHRA's Yellow Card scheme is always an option and helps build the safety picture for everyone using these medicines.

Deciding whether a higher dose is worth pursuing for you

This is the real question behind most searches on this topic. People at 1.7 mg who've lost less than they hoped want to know whether 2.4 mg will make a meaningful difference. People on 2.4 mg are now aware that 7.2 mg exists. The honest answer is that the evidence supports greater average weight loss at higher doses, but individual responses vary considerably. Some people do very well at an intermediate dose; others find the highest dose barely tolerable.

The cost of treatment is a practical factor too. If you're weighing up whether the higher-dose option fits your budget, Wegovy pricing in the UK sets out what private treatment typically involves. And if you're still deciding which treatment path makes most sense for your situation, the treatment overview gives a broader picture.

For now, the right next step is a conversation with a prescriber who can look at your specific history and response. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day. Check your eligibility to start that process.